Shire reveals positive outcome on Elvanse

18 December 2012 | 14:07pm

StockMarketWire.com - Shire has revealed a positive outcome from the European Decentralised Procedure for Elvanse, which will be known as Tyvense in Ireland.

Elvanse is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) acted as the reference member state on behalf of seven other European countries participating in the procedure (Denmark, Finland, Germany, Ireland, Norway, Spain and Sweden).

At 2:07pm: [LON:SHP] Shire Pharmaceuticals Group share price was +6.5p at 1929.5p

Story provided by StockMarketWire.com

LATEST STOCK MARKET NEWS AND OFFERS

Get the latest stock market and investment news, market wraps, promotions and more!

Shares is the leading weekly publication for high net worth private investors and stock market professionals and as such is read weekly by thousands of private investors, analysts, fund managers, stockbrokers and company directors.

Company directors know the state of their business better than anyone. That's why professional investors like to keep a close watch on the directors who are buying and selling and often follow their lead. DirectorsHoldings.com provides all the necessary screening and search tools.